UBS Group’s Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares FLAC Stock Holding History

UBS Group’s Portfolio FLAC Stock Details FLAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-970	Closed	-$10K	–	11816
2022 Q3	$10K	Buy	970 +200	+26%	+$1.99K	﹤0.01%	8540
2022 Q2	$8K	Sell	770 -81	-10%	-$799	﹤0.01%	8420
2022 Q1	$8K	Sell	851 -100	-11%	-$980	﹤0.01%	8771
2021 Q4	$9K	Sell	951 -200	-17%	-$1.96K	﹤0.01%	8983
2021 Q3	$11K	Sell	1,151 -1,828	-61%	-$17.9K	﹤0.01%	7948
2021 Q2	$29K	Buy	+2,979	New	+$29.4K	﹤0.01%	6989

UBS Group's FLAC Position: Q4 2022 in Review

UBS Group sold out of Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares (FLAC) in Q4 2022, closing a stake of 970 shares — an estimated $10K sold.

UBS Group first reported a position in FLAC in Q2 2021 and held it in 6 quarters. The position peaked at $29K in Q2 2021. 0 funds tracked by Wall St. Rank hold FLAC as of Q4 2022.

UBS Group reported no remaining Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
UBS Group sold 970 Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares shares in Q4 2022, an estimated $10K.
UBS Group first reported a position in Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares in Q2 2021 and held it in 6 quarters.
UBS Group's Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position peaked at $29K in Q2 2021.
0 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.